Detecting Thymosin Beta-4 Peptide Doping in Racehorses

Population study measuring endogenous TB4 concentrations in blood samples from racing horses across different genders, ages, and breeds. Pre-analytical stability experiments tested the effect of delayed plasma separation on TB4 concentrations. An administration study gave a single dose of a commercial TB4-containing product to a horse and tested plasma for non-natural synthesis impurities as a doping detection strategy.

TB4 is one of the most commonly discussed peptides in performance enhancement circles, marketed online for tissue repair and regeneration. This study is significant because it provides anti-doping laboratories with both baseline reference values and a concrete detection method. The finding that synthetic impurities can be detected from a single dose makes doping controls for this peptide practically feasible for the first time.

Thymosin beta-4 sits at the intersection of peptide science and anti-doping regulation. While TB4 is one of the most abundant natural peptides in mammalian cells, synthetic versions are widely sold online for their purported healing and performance-enhancing properties. This research extends beyond horse racing — the detection methodology using synthesis impurities could be adapted for human anti-doping testing, and the pre-analytical stability findings are relevant for any clinical or research use of TB4 measurements.

The administration study used a single horse with a single dose, limiting the generalizability of the impurity detection findings. The study focuses on equine physiology and may not directly translate to human TB4 reference ranges. The specific synthesis impurity detected is not named, and different manufacturers may produce products with different impurity profiles. Long-term detection windows after administration are not reported.